Novartis Licenses Abogen’s mRNA T-Cell Engager

Company Novartis / Abogen Biosciences Event Type Deal / Global License Modality mRNA-Encoded Bispecific T-Cell Engager Asset ABO2203 Target CD19 × CD3 Disease Area Refractory Autoimmune Disease Summary Novartis obtained worldwide rights to ABO2203, Abogen’s clinical-stage mRNA-encoded CD19×CD3 T-cell engager for autoimmune disease, plus options…